Dr. Michael Mullan – Medical Research Pioneer
Dr. Michael Mullan, CEO of Rockcreek Pharmaceuticals has dedicated his life’s work to discovering a prevention protocol for Alzheimer’s a devastating neurological disease that affects approximately five million Americans. As his work progresses, Dr. Mullan has developed and researched a number of cutting-edge treatment methodologies that are improving the quality of life of current Alzheimer’s patients.
The Roskamp Institute is located in Sarasota, Florida. Its mission is to “conduct scientific research to discover safe and effective new drug therapies to successfully treat diseases of the mind and promote healthy aging.” Under the leadership of Dr. Michael Mullan, the Institute’s team is vigorously working to discover the causes of and cures for a number of neurological disorders, with a special emphasis on Alzheimer’s. In addition to Alzheimer’s, Dr. Mullan and his team of international experts are addressing: Gulf War Illness, Traumatic Brain Research and other neuropsychiatric diseases.
Dedication to Alzheimer’s disease
Dr. Mullan’s special emphasis on Alzheimer’s stems from his appreciation for and desire to preserve the rich memories and historical stories of senior citizens who have so much to pass on to future generations. However, the neurological damage caused by Alzheimer’s robs the world of their wisdom and guidance. Short-term memory loss and the pain of family members who suddenly find that they are not recognized by their parent, sibling or spouse also inspires Dr. Mullan to create new, safe and effective drug treatments as quickly as possible.
Dr. Mullan attended London University from where he graduated in 1985 with a MBBS. A year before graduation, Dr. Mullan received the Hoechst Elective Award for his studies in Genetics at the Institute of Psychiatry. He went on to earn his MRCPsych from the Royal College of Psychiatry in 1990. Dr. Mullan returned to London University to pursue his PhD studies in molecular genetics, obtaining his doctorate in 1993.
Dr. Mullan is the recipient of numerous awards and recognitions for his pioneering research endeavors, such as the Ethel Williams Scholarship in 1987 awarded by the Royal Free Hospital in recognition of his postgraduate research into Alzheimer’s disease. He has published more than 200 research papers on the subjects of Alzheimer’s disease, schizophrenia, alcohol abuse, molecular genetics, manic-depression disorder and dementia. Dr. Mullan personally holds more than 12 patents and has received a number of research grants from various government and private institutions to investigate the causes and prevention of Alzheimer’s disease.
Dr. Michael Mullan began his career in psychiatry in 1988 at the Royal Free Hospital where he served as Senior Registrar. During this time, Dr. Mullan was also the house physician for two other hospitals: Harrogate General and Royal East Sussex Hospital. During this time, Dr. Mullan focused on psychiatric and geriatrics care. In 1994, he became director at Roskamp Laboratories, and then Professor of Psychiatry at Roskamp Institute in 2003 until ultimately becoming CEO and President in 2003, till 2013. Dr. Mullan became CEO of Rockcreek Pharmaceuticals and heading the development of Anatabloc as an anti-inflammatory agent.
Dr. Michael Mullan is currently the CEO of Rockcreek Pharmaceuticals. He successfully lead a number of scientific initiatives examining the genetic causes of Alzheimer’s, and the development of new and safe drug therapies to address the problems of neurodegenerative and neuropsychiatric diseases and addictions.